- •Abuse liability of the tapentadol active pharmaceutical ingredient (API) is compared with those of other scheduled opioids.
- •Population-level event rates of tapentadol API abuse were lower than comparators.
- •Drug availability adjusted event rates of tapentadol abuse were low but not lowest.
- •Public health burden of tapentadol API appears to be low.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Abuse risks and routes of administration of different prescription opioid compounds and formulations.Harm Reduct J. 2011; 8: 29
- Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.J Pain. 2013; 14: 351-358
- Tapentadol abuse potential: A postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment.Pain Med. 2015; 16: 119-130
- Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse.Clin J Pain. 2014; 30: 1051-1056
- Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.J Pain. 2013; 14: 1227-1241
- Comparison of opioid doctor shopping for tapentadol and oxycodone: a cohort study.J Pain. 2013; 14: 158-164
- Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources.Clin J Pain. 2012; 28: 8-13
- Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin.JAMA Psychiatry. 2015; 72: 424-430
- Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994–2004.Pharmacoepidemiol Drug Saf. 2005; 14: 851-859
- Nonmedical use of tapentadol immediate release by college students.Clin J Pain. 2014; 30: 685-692
- Assessment of the abuse of tapentadol immediate release: The first 24 months.J Opioid Manag. 2012; 8: 395-402
- Trends in opioid analgesic abuse and mortality in the United States.N Engl J Med. 2015; 372: 241-248
- Diversion and Illicit sale of extended release tapentadol in the United States.Pain Med. 2016; 17: 1490-1496
- Using poison center exposure calls to predict methadone poisoning deaths.PLoS One. 2012; 7 (e41181)
- Crowdsourcing black market prices for prescription opioids.J Med Internet Res. 2013; 15: e178
- Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits.Pharmacoepidemiol Drug Saf. 2014; 23: 18-25
- Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: Results of in vitro laboratory analyses.J Opioid Manag. 2014; 10: 149-158
- Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.Pharmacol Res. 2015; 91: 99-103
- Impact of abuse-deterrent OxyContin on prescription opioid utilization.Pharmacoepidemiol Drug Saf. 2015; 24: 197-204
- The “black box” of prescription drug diversion.J Addict Dis. 2009; 28: 332-347
- The diversion of prescription opioid analgesics.Law Enforc Exec Forum. 2007; 7: 127-141
- Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States.Pharmacoepidemiol Drug Saf. 2011; 20: 819-826
- Comparing prescription opioids, methadone, and heroin endorsement rates from the treatment episode data set to the RADARS system treatment center programs.Radars Syst Tech Rep. 2016; Q3: 1-4
- Assessing abuse potential of new analgesic medications following market release: An evaluation of Internet discussion of tapentadol abuse.Pain Med. 2015; 16: 131-140
- 2014 annual report of the american association of poison control centers' national poison data system (NPDS): 32nd annual report.Clin Toxicol. 2015; 53: 962-1147
- Mechanistic and functional differentiation of tapentadol and tramadol.Expert Opin Pharmacother. 2012; 13: 1437-1449
- Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.Drug Alcohol Depend. 2016; 168: 219-229
- Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids.Am J Drug Alcohol Abuse. 2006; 32: 465-478
- Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.Psychopharmacology (Berl). 2013; 228: 255-262
- The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: The case of tapentadol.CNS Drugs. 2014; 28: 319-329
- Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.Drugs Today (Barc). 2009; 45: 483-496
- National Forensic Laboratory Information System Special Report: Opiates and Related Drugs Reported in NFLIS 2009–2014.US Drug Enforcement Administration, Springfield, VA2015
- National Forensic Laboratory Information System: Midyear Report 2015.U.S. Drug Enforcement Administration, Springfield, VA2016
- A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin(R) (non-TRF) in prescription opioid abusers.Addiction. 2013; 108: 1095-1106
- Analysis of the abuse and diversion of the buprenorphine transdermal delivery system.J Pain. 2016; 17: 745-752
- A difficult balance–pain management, drug safety, and the FDA.N Engl J Med. 2009; 361: 2105-2107
- Tramadol Update Review Report.World Health Organization, Geneva, Switzerland2014
The Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System is supported by subscriptions from pharmaceutical manufacturers for surveillance, research and reporting services. The RADARS System is the property of Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases, and systems. Subscribers do not participate in data collection or analysis, nor do they have access to the raw data. Depomed is a RADARS System subscriber. Scientists from Depomed reviewed the draft manuscript for propriety information, however, all final content decisions were made by the RADARS System.
S.K.V. is a scientific consultant with RADARS System and received compensation for preparation of this article. S.K.V. has consulted with Grünenthal, USA. T.J.C., S.P.K., and M.W.P. are compensated for participation on the RADARS System Scientific Advisory Board, and DHHA contracts with these authors' institutions for the operation of RADARS System programs that provided some of the data for this study. S.G.S., R.C.D. and J.L.D. are employees of DHHA.